Vivo Bio Tech logo

Vivo Bio Tech financials: balance sheet, profit and loss, cash flow

NSE: VIVOBIOTBSE: 511509Pharmaceuticals & BiotechnologySmall Cap

Vivo Bio Tech Limited · Face value ₹10 · Listed Aug 1994
Last close ₹13.98up ₹0.11 (0.79%)BSE ₹13.95

Share price at the NSE close on 29 Oct 2026. Previous close ₹13.87.

29 Oct: open ₹13.58, high ₹14.09, low ₹13.49

52-week range of BSE trades to 29 Oct 2026
₹12.20Low, 26 Oct 2026₹35.76High, 13 Nov 2025
Market cap
₹31 Cr3,302nd largest listed
P/E
Lossover the last 12 months
P/B
0.33
Dividend yield
Nonein the last 12 months
ROE
−3.3%
ROE without one-offs
−2.6%
ROCE
5.9%
Debt to equity
0.72
Volume, NSE
8,84371.4% delivered

Vivo Bio Tech's financial statements for the 10 years to Mar 2026, standalone: the listed company alone, without its subsidiaries, with the twelve months to Jun 2026 after them.

10 years at a glance

₹ crore, years to March.Vivo Bio Tech annual reports

Revenue, net profit and borrowings, ₹ crore

  • Revenue
  • Net profit
  • Borrowings
  • Loss
342.5Mar 17473.1Mar 18562.3Mar 19554.422Mar 20525.729Mar 21512.265Mar 22522.660Mar 23452.571Mar 24477.652Mar 2553−1.964Mar 26
Peak revenue ₹56 Cr, year to Mar 2019; lowest ₹34 Cr, year to Mar 2017A loss in the year to Mar 2026, −₹1.94 Cr

Operating and net margin, per cent

  • Operating margin
  • Net margin
47.0%−3.7%23.2%23.8%22.5%34.1%30.8%41.6%47.0%44.6%40.4%7.3%6.6%4.0%8.0%11.0%4.3%5.1%5.6%16.2%−3.7%Mar 17Mar 19Mar 21Mar 23Mar 25Mar 26

Results for the year to Mar 2026

Standalone: the listed company alone, without its subsidiaries. ₹ crore.

From revenue to net profit

  1. Revenue53
  2. Materials and goods−8.1
  3. Employee costs−16
  4. Other expenses−7.3
  5. Operating profit21
  6. Depreciation−11
  7. Other income+0.4
  8. One-off items−0.6
  9. Finance costs−5.8
  10. Profit before tax4.6
  11. Tax−6.5
  12. Net profit−1.9

What the company owns

  • Plant, investments and other assets₹154 Cr
  • Receivables₹12 Cr
  • Inventory₹8 Cr
  • Cash and bank₹1 Cr

What pays for it: net worth and liabilities

  • Net worth₹93 Cr
  • Borrowings₹64 Cr
  • Other liabilities₹16 Cr
  • Owed to suppliers₹2 Cr

Profit and loss

Standalone, ₹ crore, years to March. The last column is the twelve months to Jun 2026, the latest four quarters added.Vivo Bio Tech quarterly results

₹ croreMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026Filed 30 MayJun 2026Twelve monthsFiled 13 Jul
Revenue from operations34.147.055.855.451.851.451.644.946.752.654.3
–36.142.542.934.135.630.123.825.931.333.5
Materials and goods bought8.69.612.48.67.211.46.83.85.88.18.5
Employee costs–––10.08.69.413.210.111.916.017.5
Other expenses–––24.318.314.710.29.88.27.37.6
Operating profit before depreciation–10.913.312.517.715.821.521.120.821.220.7
Operating margin–23.2%23.8%22.5%34.1%30.8%41.6%47.0%44.6%40.4%38.2%
Materials, % of revenue–––15.5%13.9%22.3%13.1%8.6%12.4%15.5%15.6%
Employee costs, % of revenue–––18.1%16.6%18.3%25.5%22.6%25.4%30.3%32.2%
Other expenses, % of revenue–––43.9%35.4%28.6%19.8%21.9%17.6%13.8%14.0%
Depreciation and amortisation3.94.65.15.25.67.49.39.39.010.611.5
Operating profit after depreciation–6.28.27.312.18.412.211.811.810.69.2
Other income0.40.10.00.10.10.10.00.04.80.40.4
Finance costs–2.42.63.13.54.07.77.87.55.85.6
Profit before one-off items and tax2.84.05.64.38.64.54.64.19.15.24.0
One-off items––−3.80.00.00.00.00.00.0−0.6−0.6
Profit before tax2.84.01.84.38.64.54.64.19.14.63.4
0.30.9−0.4−0.22.92.32.01.51.56.56.5
Net profit2.53.12.34.45.72.22.62.57.6−1.9−3.1
Net margin7.3%6.6%4.0%8.0%11.0%4.3%5.1%5.6%16.2%−3.7%−5.8%
Materials, employee costs and other expenses are shown for the years they add up to operating expenses; for the years to Mar 2018 and Mar 2019 they do not, so they are left blank. Operating expenses, operating profit before depreciation and operating profit after depreciation are left blank for the year to Mar 2017: the statement does not state its finance costs, which operating profit is worked out from, so operating profit is not given.
Earlier years, Mar 2010 to Mar 2016
₹ croreMar 2010Mar 2011Mar 2012Mar 2013Mar 2014Mar 2015Mar 2016
Revenue from operations3.69.112.514.416.117.828.6
3.34.47.312.014.415.024.9
Materials and goods bought–––3.72.73.18.2
Employee costs––––2.2––
Other expenses––––9.5––
Operating profit before depreciation0.34.75.22.41.72.83.7
Operating margin7.5%52.1%41.8%16.6%10.8%15.8%13.0%
Materials, % of revenue––––16.7%––
Employee costs, % of revenue––––13.8%––
Other expenses, % of revenue––––58.7%––
Depreciation and amortisation1.12.22.41.61.63.03.4
Operating profit after depreciation−0.82.62.90.80.2−0.20.4
Other income0.50.1–0.70.90.90.9
Finance costs0.72.73.40.80.40.50.5
Profit before tax−0.90.0−0.60.80.70.20.8
Tax0.1−0.3−0.30.50.4−0.3−0.1
Net profit−1.00.3−0.30.20.30.50.9
Net margin−27.7%3.4%−2.3%1.7%1.8%2.6%3.2%
Standalone, ₹ crore, years to March.

Balance sheet

Standalone, ₹ crore, at 31 March.

₹ croreMar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026Filed 30 May
33434752547893
Share capital13131415151722
Reserves20293337396171
22296560715264
21222325382830
6135044433552
Total assets6077120121135141175
324993888798147
28282733484328
Net debt21286459705163
Borrowings are counted again inside the liabilities due within a year and after a year. No balance sheet is on record for the years to Mar 2017, Mar 2018 and Mar 2019, so its lines and the ratios worked from it are blank there.

Cash flow

Standalone, ₹ crore, years to March.

₹ croreMar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026Filed 30 May
14.113.68.415.811.836.1
20.619.917.119.015.938.7
2.84.0−4.4−2.1−5.017.6
Receivables1.51.1−6.3−15.04.815.2
Payables1.42.91.912.9−9.92.4
Tax paid−2.9−2.3−1.0−1.7−2.1−0.8
Interest paid−3.5−4.0−7.7−1.5−2.0−1.8
Capital spending22.851.14.08.00.237.4
Free cash flow−8.7−37.54.47.911.6−1.3
−22.8−51.1−4.0−8.0−15.8−59.3
8.837.9−4.9−7.63.923.3
Dividends paid0.00.00.00.00.00.0
Shares bought back0.00.00.00.00.00.0
Shares issued3.82.42.10.016.217.0
Net change in cash0.10.4−0.50.3−0.10.1
Capital spending is part of cash from investing, and dividends paid, shares bought back and shares issued are part of cash from financing. Each is shown as an amount on a line of its own, and the section's other items are in its total only. No cash flow statement is on record for the years to Mar 2017, Mar 2018, Mar 2019 and Mar 2020.

Per share

Standalone, ₹ per share, years to March.

₹ per shareMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026Filed 30 May
Earnings per share₹2.68₹3.18₹1.82₹3.45₹4.24₹1.56₹1.77₹1.69₹4.95−₹0.93
Diluted earnings per share₹2.68₹2.48₹1.76₹3.45₹4.20₹1.56₹1.77₹1.51₹4.95−₹0.93
Book value per share–––₹25.63₹31.70₹33.05₹34.81₹36.50₹45.55₹42.01
Shareholder yield––––−6.2%−4.3%−7.3%0.0%−28.3%−36.5%
Market cap at the year end (₹ crore)93.552.155.125.061.756.328.763.957.346.5

Ratios

Standalone, years to March.Vivo Bio Tech PE ratio and valuation

RatioMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026Filed 30 May
Revenue growth19.4%37.7%18.8%−0.9%−6.5%−0.7%0.4%−13.1%4.0%12.6%
Operating profit growth––22.2%−6.2%41.6%−10.5%35.9%−1.9%−1.4%2.0%
Net profit growth175.2%24.7%−28.0%97.5%27.9%−61.2%19.5%−4.2%200.2%–
Earnings per share growth–18.7%−42.8%89.6%22.8%−63.2%13.5%−4.5%192.9%–
–––13.5%15.0%4.9%5.3%4.7%11.4%−2.3%
––––1.6 pts−10.1 pts0.4 pts−0.6 pts6.7 pts−13.7 pts
From the net margin––––4.9 pts−9.2 pts0.9 pts0.5 pts9.0 pts−14.0 pts
From asset turnover––––−3.4 pts−1.8 pts−1.0 pts−1.1 pts−0.5 pts0.0 pts
From borrowing––––0.0 pts0.9 pts0.5 pts−0.1 pts−1.8 pts0.3 pts
Return on capital employed–––13.2%16.9%7.5%10.9%9.4%9.1%6.7%
Cash conversion––––248.0%618.3%320.5%627.6%156.3%–
Interest cover–2.63.12.43.42.11.61.51.61.8
Debt to equity–––0.670.681.381.161.300.660.69
Receivable days–––69518588928882
Inventory days–––451672313430832491366
Payable days–––167707451101081
Cash conversion cycle, days–––353654325467824579367
Working capital days–––139152141185328261122
Asset turnover–––0.920.750.520.430.350.340.33
Assets per rupee of net worth–––1.811.822.202.432.412.081.84
Sales per rupee of plant–––2.191.390.660.690.650.760.77
Capital spending to depreciation––––4.086.870.430.860.033.52
Plant being built, % of plant in use–––0.6%0.9%1.1%2.5%13.4%21.1%7.0%
No balance sheet is on record for the years to Mar 2017, Mar 2018 and Mar 2019, so its lines and the ratios worked from it are blank there.

Growth and returns over 3, 5 and 10 years

Standalone: the listed company alone, without its subsidiaries. Each window ends with the year to Mar 2026.

Return on assets, latest year
−1.2%
Cash from operations against operating profit
170.1%
Measure10 years5 years3 years
Revenue growth, yearly rate6.3%0.3%0.6%
Return on equity, average–4.8%4.6%
Return on capital employed, average–8.7%8.4%
Operating margin, average34.2%40.9%44.0%
Net margin, average6.5%5.5%6.1%
Asset turnover, average–0.390.34
Cash conversion cycle, days, average–512590
Interest cover, average2.21.71.6
Debt to equity, average–1.040.88

Where the cash came from and went

Standalone: the listed company alone, without its subsidiaries. ₹ crore, added up over each window, which ends with the year to Mar 2026.

₹ crore5 years3 yearsLatest year
Cash from operations866436
Cash from investing−138−83−59
Cash from financing532023
Capital spending1014637
Dividends paid000
Shares bought back000
Shares issued for cash383317
Borrowings raised––10
Borrowings repaid000

Accounting checks

Standalone, years to March. Published tests of whether reported profit is backed by cash and the balance sheet.

CheckMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Effective tax ratePublished threshold 17.16 per cent11.7122.08−23.15–––––––
A threshold marked as ours has no published figure; it is the line we read the check against.

Credit ratings

An agency's view of the chance the company repays a borrowing on time, from AAA, the highest, down to D, in default.

DateAgencyBorrowing ratedRatingOutlookAmount, ₹ Cr
17 Nov 2025Acuite Ratings & Research LimitedBank Loan RatingsLong-term scaleACUITE BBB-NAStable39.29
17 Nov 2025Acuite Ratings & Research LimitedBank Loan RatingsShort-term scaleACUITE A3NA2
17 Nov 2025Acuite Ratings & Research LimitedBank Loan RatingsLong-term scaleNot ApplicableRating Withdrawn15.40
The latest rating on each borrowing. The agency's name opens its reasoning for the rating.